A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities
2001
A Phase I trial was conducted to determine the safety, biological
activity, and hematopoietic recovery by the combination of interleukin
6 (IL-6) and granulocyte-colony stimulating factor (G-CSF) after
myelosuppressive chemotherapy in children. Patients <22 years of age
at diagnosis with either recurrent or refractory solid tumors received
ifosfamide 1,800 mg/m 2 /day × 5 days, carboplatin
400 mg/m 2 /day × 2 days, and etoposide 100
mg/m 2 /day × 5 days, followed by daily s.c. G-CSF (5μ
g/kg/day) and IL-6 (2.5, 3.75, or 5.0 μg/kg/day). Pharmacokinetic,
proinflammatory mediator levels, hematopoietic colony assays, and
cytokine receptor expression studies were performed during course one.
Nineteen patients were evaluable for toxicity and received IL-6 at
doses of 2.5 ( n = 8), 3.75 ( n =
5), or 5.0 ( n = 6) μg/kg/day. Dose-limiting
constitutional toxicity occurred in two of six patients at 5.0μ
g/kg/day, two of five patients at 3.75 μg/kg/day, and two of eight
patients at 2.5 μg/kg/day. The maximum tolerated dose (MTD) exceeded
the lowest dose tested. Because of lack of drug availability, an MTD
was not established. The maximum concentration of IL-6 (2.5μ
g/kg/day) was 0.799 ± 1.055 ng/ml (mean ± SD). During
the first course, the median time to absolute neutrophil count≥
1,000/mm 3 and platelets ≥100,000 mm 3 was
estimated at 19 and 23 days, respectively. Peripheral blood progenitor
cells expressing receptors to IL-3, IL-6, and G-CSF increased
significantly over baseline ( P < 0.05). After the
first dose of IL-6, IFN-γ levels were abnormal in 13 patients, and
IL-1β levels were abnormal in 10 patients. IL-6 has a high incidence
of constitutional toxicity and a lower MTD in children compared with
adults. In vivo use of IL-6 in children after
chemotherapy remains limited. However, IL-6 may be more optimally
investigated in children under ex vivo conditions.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
16
Citations
NaN
KQI